Table of contents
April 2007 Volume 3 No 4
Editorial
Viewpoint
How important is echocardiography for risk stratification in follow-up of patients with chronic kidney disease?
178Focusing largely on end-stage renal disease, this Viewpoint outlines some echocardiographic indices of left ventricular function, and examines their prognostic value in chronic kidney disease. Recommendations are provided for optimal indexing of estimates of left ventricular mass to body size in this population. The role of echocardiography as an outcome measure in interventional studies and in the longitudinal monitoring of cardiac risk are also briefly considered.
Research Highlights
Tolvaptan increases serum sodium concentrations in hyponatremic patients
180MRI estimates size of normal kidneys more accurately than standard methods
180Is serum NGAL an accurate marker of renal function in pediatric CKD?
180Agalsidase beta slows the progression of advanced Fabry's disease
181Lowering blood pressure could protect against renal dysfunction in type 1 diabetes
181Spironolactone add-on therapy decreases proteinuria in diabetic nephropathy
182Rosiglitazone can be used for diabetes control in hemodialysis patients with hepatitis
182Peritoneal dialysis solution containing amino acids and glucose improves protein synthesis
183Highly variable effects of islet transplantation on renal function in type 1 diabetics
183Cooled dialysate ameliorates hemodialysis-induced left ventricular dysfunction
184Use of an abdominal band reduces postdialytic orthostatic hypotension in some patients
184Survival after cardiac arrest in HD clinic unimproved by access to external defibrillator
184Practice Points
Modified MDRD equations outperform the original equations in Chinese patients with chronic kidney disease
186Cystatin C as a marker of glomerular filtration rate in chronic kidney disease: influence of body composition
188Is low-dose ciclosporin an effective treatment for membranous nephropathy with nephrotic syndrome?
190Case-mix factors explain the survival advantage of Hispanic and racial minority patients on hemodialysis
192High rates of coronary artery stenosis detected by angiography in diabetic renal transplant candidates
194Immune function, as assessed by the ImmuKnow® assay, correlates with clinical outcomes in transplant recipients
196Reviews
Therapy Insight: sexual dysfunction in patients with chronic kidney disease
200Decreased libido, difficulty becoming aroused and achieving orgasm, erectile and ejaculatory dysfunction, and lack of vaginal lubrication are common problems that have a substantial impact on the quality of life of people with chronic kidney disease. This guide to the assessment and management of sexual dysfunction in renal patients emphasizes the multifactorial nature of such problems, and the need for medical teams to initiate discussion of sexual issues as part of routine care.
doi:10.1038/ncpneph0438 | Full Text | PDF (203K)
Mechanisms of Disease: the tissue kallikrein–kinin system in hypertension and vascular remodeling
208Kinins are endogenous vasodilators, through which at least some of the beneficial cardiovascular effect of ACE inhibitors is exerted. In the past 15 years, development of new research tools has contributed to the generation of many genetic, biochemical and clinical data. Here, these new findings are brought together to illustrate the potential for manipulation of the kallikrein–kinin system to ameliorate hypertension and its complications, including cardiac hypertrophy and renal failure.
doi:10.1038/ncpneph0444 | Full Text | PDF (557K)
Case Studies

Polycythemia and increased erythropoietin in a patient with chronic kidney disease
222doi:10.1038/ncpneph0437 | Full Text | PDF (401K)
Osteomalacia in a hemodialysis patient receiving an active vitamin D sterol
227doi:10.1038/ncpneph0443 | Full Text | PDF (233K)
Corrigendum
Book Review
Article Responses
Author's response to "Optimal paricalcitol starting dose for parathyroid hormone suppression in secondary hyperparathyroidism"
E1doi:10.1038/ncpneph0449 | Full Text
Optimal paricalcitol starting dose for parathyroid hormone suppression in secondary hyperparathyroidism
E2doi:10.1038/ncpneph0442 | Full Text


